{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:50:06Z","timestamp":1769665806913,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences & Peking Union Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2023-I2M-2\\u2013009"],"award-info":[{"award-number":["2023-I2M-2\\u2013009"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.118020","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:31:53Z","timestamp":1754436713000},"page":"118020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of potent and selective STAT3 inhibitors against triple-negative breast cancer"],"prefix":"10.1016","volume":"298","author":[{"given":"Ru","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Dong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei-Bei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Ting","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9496-2280","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118020_bib1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrc3818","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions","volume":"14","author":"Yu","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118020_bib2","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.7701321","article-title":"Requirement of serine phosphorylation for formation of STAT-promoter complexes","volume":"267","author":"Zhang","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118020_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110275","article-title":"Importance of STAT3 signalling in cancer, metastasis and therapeutic interventions","volume":"92","author":"El-Tanani","year":"2022","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2025.118020_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","article-title":"STAT proteins in cancer: orchestration of metabolism","volume":"23","author":"Li","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118020_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13058-025-02074-x","article-title":"Cancer-associated fibroblast driven paracrine IL-6\/STAT3 signaling promotes migration and dissemination in invasive lobular carcinoma","volume":"27","author":"Bullock","year":"2025","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118020_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104620","article-title":"STAT3 orchestrates immune dynamics in hepatocellular carcinoma: a pivotal nexus in tumor progression","volume":"207","author":"Zhang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2025.118020_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118020_bib8","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118020_bib9","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118020_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer-expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118020_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejmech.2025.118020_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118020_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118020_bib14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118020_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102672","article-title":"Breaking barriers in triple negative breast cancer (TNBC)-Unleashing the power of antibody-drug conjugates (ADCs)","volume":"123","author":"Dri","year":"2024","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2025.118020_bib16","doi-asserted-by":"crossref","first-page":"20517","DOI":"10.18632\/oncotarget.15259","article-title":"TNBC invasion: downstream of STAT3","volume":"8","author":"Jackson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118020_bib17","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2304081120","article-title":"A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis","volume":"120","author":"Kim","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118020_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101004","article-title":"Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer","volume":"71","author":"Bharathiraja","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2025.118020_bib19","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.drudis.2020.11.032","article-title":"Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance","volume":"26","author":"Shih","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118020_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118020_bib21","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.2174\/0929867328666201207202012","article-title":"Targeting the JAK\/STAT signaling pathway for breast cancer","volume":"28","author":"Shao","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118020_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcancer.2022.08.003","article-title":"STAT family of transcription factors in breast cancer: pathogenesis and therapeutic opportunities and challenges","volume":"86","author":"Wong","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118020_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118020_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semcancer.2019.09.022","article-title":"Repurposing of drugs as STAT3 inhibitors for cancer therapy","volume":"68","author":"Thilakasiri","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118020_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030492","article-title":"Exploring novel frontiers: leveraging STAT3 signaling for advanced cancer therapeutics","volume":"16","author":"Adesoye","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.118020_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117382","article-title":"Research progress of STAT3-based dual inhibitors for cancer therapy","volume":"91","author":"Yang","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118020_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2024.110447","article-title":"Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: an updated review (from 2022 to 2024)","volume":"36","author":"Kang","year":"2025","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118020_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122635","article-title":"Enhancing cancer therapy: the role of drug delivery systems in STAT3 inhibitor efficacy and safety","volume":"346","author":"Wang","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.118020_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107565","article-title":"Design, synthesis and biological evaluation of novel naphthoquinothiazole derivatives as potent antitumor agents through inhibiting STAT3","volume":"150","author":"Fan","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118020_bib30","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","article-title":"Stattic: a small-molecule inhibitor of STAT3 activation and dimerization","volume":"13","author":"Schust","year":"2006","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118020_bib31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41401-021-00718-0","article-title":"The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts","volume":"43","author":"Zhong","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118020_bib32","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1073\/pnas.0609757104","article-title":"Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity","volume":"104","author":"Siddiquee","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118020_bib33","doi-asserted-by":"crossref","first-page":"9623","DOI":"10.1073\/pnas.1121606109","article-title":"Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts","volume":"109","author":"Zhang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118020_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113564","article-title":"Design, synthesis and biological evaluation of N-anthraniloyl tryptamine derivatives as pleiotropic molecules for the therapy of malignant glioma","volume":"222","author":"Fan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118020_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117332","article-title":"Structural optimization and characterization of highly potent and selective STAT3 inhibitors for the treatment of triple negative breast cancer","volume":"287","author":"Jin","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118020_bib36","doi-asserted-by":"crossref","first-page":"12650","DOI":"10.1021\/acs.jmedchem.2c00413","article-title":"Discovery of a novel potent STAT3 inhibitor HP590 with dual p-Tyr(705)\/Ser(727) inhibitory activity for gastric cancer treatment","volume":"65","author":"He","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118020_bib37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118020_bib38","doi-asserted-by":"crossref","first-page":"12493","DOI":"10.1021\/acs.jmedchem.5c00126","article-title":"Discovery of diaryl piperidone-sulfonamide as a novel dual-target inhibitor of STAT3\/CAIX inducing ferroptosis in triple-negative breast cancer cells","volume":"68","author":"Chen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118020_bib39","first-page":"100","article-title":"Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C study","volume":"22","author":"Shah","year":"2023","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ejmech.2025.118020_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40268-023-00416-8","article-title":"A phase I study to investigate the safety, tolerability and pharmacokinetics of Napabucasin combined with Sorafenib in Japanese patients with unresectable hepatocellular carcinoma","volume":"23","author":"Okusaka","year":"2023","journal-title":"Drugs R&D"},{"key":"10.1016\/j.ejmech.2025.118020_bib41","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","article-title":"Phase I trial of TTI-101, a first-in-class oral inhibitor of STAT3, in patients with advanced solid tumors","volume":"31","author":"Tsimberidou","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118020_bib42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/CAD.0000000000001376","article-title":"Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification","volume":"34","author":"Cerretti","year":"2023","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejmech.2025.118020_bib43","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/hep.31812","article-title":"Analysis and validation of human targets and treatments using a hepatocellular carcinoma-immune humanized mouse model","volume":"74","author":"Zhao","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.118020_bib44","doi-asserted-by":"crossref","first-page":"20495","DOI":"10.1021\/acs.jmedchem.4c01946","article-title":"Discovery of SD-436: a potent, highly selective and efficacious STAT3 PROTAC degrader capable of achieving complete and long-lasting tumor regression","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118020_bib45","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41586-025-09000-3","article-title":"STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity","volume":"643","author":"Zhou","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118020_bib46","doi-asserted-by":"crossref","first-page":"12373","DOI":"10.1021\/acs.jmedchem.3c00863","article-title":"Discovery, optimization, and evaluation of novel N-(benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine analogues as potent STAT3 inhibitors for cancer treatment","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118020_bib47","doi-asserted-by":"crossref","first-page":"13094","DOI":"10.1021\/acs.jmedchem.2c00940","article-title":"Boronic acid: a novel pharmacophore yargeting Src homology 2 (SH2) domain of STAT3","volume":"65","author":"Deng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118020_bib48","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1021\/jm300207s","article-title":"Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein","volume":"55","author":"Debnath","year":"2012","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T17:51:17Z","timestamp":1769622677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":48,"alternative-id":["S0223523425007858"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118020","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent and selective STAT3 inhibitors against triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118020"}}